There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BCMA


BCMA Molecule Information

Name:B-cell maturation protein
Target Synonym:Tumor necrosis factor receptor superfamily member 17;B-cell maturation protein;CD_antigen: CD269;BCMA;TNFRSF17;BCM
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Phase ?

BCMA Part of Bioactivity data

BCA-HF2H1-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1, 1 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) (QC tested).


Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 32.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Anti-BCMA MAb (Mouse IgG1, the antibody was co developed by SCT and ACRObiosystems) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCMA Protein Product ListCompare or Buy

BCMA Customer Reviews

BCMA Molecule Synonym Name


BCMA Molecule Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

BCMA References

BCMA Related Molecule

BCMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase Ⅰ The First Affiliated Hospital of Nanchang University Multiple myeloma (MM) Details
TNB-383B TNB-383B Phase Ⅰ Teneobio, Abbvie Multiple myeloma (MM) Details
LCAR-B38M cell product JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 Phase Ⅲ Nanjing Chuanqi Biotech, Janssen Multiple myeloma (MM) Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase Ⅰ Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple myeloma (MM) Details
BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Multiple myeloma (MM) Details
Belantamab mafodotin GSK-2857916 BLA Filing GlaxoSmithKline Multiple myeloma (MM) Details
Idecabtagene vicleucel bb-2121 BLA Filing bluebird bio, Celgene Multiple myeloma (MM) Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase Ⅱ General Hospital of the People's Liberation Army Multiple myeloma (MM) Details
GC-012F GC-012F Phase Ⅰ Gracell Biotechnology Multiple myeloma (MM) Details
CART-BCMA CART-BCMA; MTV-273,CART BCMA,MTV273 Phase Ⅰ University of Pennsylvania, Novartis Multiple myeloma (MM) Details
P-BCMA-101 P-BCMA-101 Phase Ⅱ Poseida Therapeutics Multiple myeloma (MM) Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Phase Ⅱ Asclepius Technology Company Group Multiple myeloma (MM) Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM) Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase Ⅰ Arcellx Multiple myeloma (MM) Details
HPN-217 HPN-217 Phase Ⅱ Harpoon Therapeutics, Abbvie Multiple myeloma (MM) Details
CC-99712 CC-99712 Phase Ⅰ Celgene Multiple myeloma (MM) Details
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) CT103A Phase Ⅰ Innovent Biologics, Nanjing IASO Biotherapeutics Multiple myeloma (MM) Details
MEDI-2228 MEDI-2228,MEDI 2228,MEDI2228 Phase Ⅰ MedImmune Multiple myeloma (MM) Details
SEA-BCMA SEA-BCMA; SGN-BCMA Phase Ⅰ Seattle Genetics Multiple myeloma (MM) Details
PBCAR-269A PBCAR-269A Phase Ⅱ Precision BioSciences Multiple myeloma (MM) Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Phase Ⅰ PersonGen Biomedicine, Second Affiliated Hospital of Suzhou UniversitySecond Affiliated Hospital of Suzhou University Multiple myeloma (MM) Details
BCMA CAR-T Cells (Pregene) Phase Ⅰ Pregene Multiple myeloma (MM) Details
bb-21217 bb-21217,bb 21217,bb21217 Phase Ⅰ bluebird bio, Celgene Multiple myeloma (MM) Details
AMG-420 AMG-420; BI-836909 Phase Ⅰ Micromet, Boehringer Ingelheim, Amgen Multiple myeloma (MM) Details
KITE-585 KITE-585,KITE585 Phase Ⅰ Kite Pharma, National Cancer Institute Multiple myeloma (MM) Details
REGN-5459 REGN-5459 Phase Ⅱ Regeneron Pharmaceutical Multiple myeloma (MM) Details
PF-06863135 PF-06863135,PF 06863135 Phase Ⅰ Pfizer Multiple myeloma (MM) Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM), Lymphoma Details
LCAR-B4822M LCAR-B4822M,LCAR B4822M,LCARB4822M Phase Ⅰ GenScript Biotech Corporation Multiple myeloma (MM) Details
CAR-BCMA T cell therapy CT-053-CARsgen Phase Ⅰ CARsgen Therapeutics Multiple myeloma (MM) Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase Ⅰ Shanghai Hrain Biotechnology Multiple myeloma (MM) Details
JNJ-64007957 JNJ-7957; JNJ-64007957; JNJ-64007959 Phase Ⅰ Janssen, Genmab Multiple myeloma (MM) Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech) Phase Ⅱ Chongqing Precision Biotech Plasma cell neoplasms, Multiple myeloma (MM) Details
AUTO-2 AUTO-2; SUB-96123,AUTO 2; SUB 96123 Phase Ⅱ Autolus Multiple myeloma (MM) Details
CC-93269 CC-93269; EM-901 Phase Ⅰ Celgene Multiple myeloma (MM) Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) Phase Ⅲ The First Affiliated Hospital of Soochow University Multiple myeloma (MM) Details
ACTR 087/SEA BCMA combination therapy Phase Ⅰ Unum Therapeutics, Seattle Genetics Multiple myeloma (MM) Details
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171 Phase Ⅱ Juno Therapeutics Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
ALLO-715 ALLO-715 Phase Ⅰ Allogene Therapeutics, Cellectis Multiple myeloma (MM) Details
BCBM CAR T cell (Pregene) Phase Not Specified Pregene, BioCast Multiple myeloma (MM) Details

This web search service is supported by Google Inc.